Our Services
Medical Information
Helpful Resources
Published on: 10/26/2026
Zyprexa (olanzapine) is linked to significant weight gain, increased appetite, high blood sugar, elevated cholesterol and triglycerides, and in some cases new-onset type 2 diabetes, which is why clinicians track weight, BMI, waist circumference, fasting glucose or A1c, and a lipid panel at baseline and at regular intervals, along with blood pressure, sedation, and movement-related effects. How quickly these changes appear, which ones are reversible, and when a dose adjustment, added medication, or switch to a lower-risk antipsychotic makes sense all depend on your personal history, so there are several important factors to consider below. Sudden warning signs such as excessive thirst, frequent urination, confusion, high fever with muscle stiffness, or uncontrolled movements need urgent medical attention rather than watchful waiting. Because weight and metabolic shifts can also come from thyroid problems, other medications, sleep issues, or diet changes, sorting out the actual cause matters before you change anything about your treatment. Take a free, instant, online symptom check to see how your symptoms line up, understand which ones deserve priority, and walk into your next appointment with clear questions and a sensible plan for monitoring.
Last reviewed for medical accuracy: 10/22/2026
Zyprexa (generic name: olanzapine) is an atypical antipsychotic commonly prescribed for conditions such as schizophrenia and bipolar disorder. While many people benefit from its symptom-relieving effects, it’s important to understand the potential zyprexa side effects, particularly those related to weight gain and metabolic changes. This guide breaks down what you need to know, how monitoring works, and steps you can take to stay healthy—without sugar-coating the facts.
Most people tolerate Zyprexa well, but some side effects may occur. These typically range from mild to moderate:
Weight gain and metabolic changes are among the most significant concerns, as they can lead to long-term health issues if not addressed.
Zyprexa’s tendency to cause weight gain is well documented. Several mechanisms may contribute:
Over weeks to months, these effects often combine to produce noticeable weight gain—sometimes 5–15 pounds or more in the first few months.
Beyond weight gain, Zyprexa can impact key metabolic markers. This cluster of changes is called “metabolic syndrome” and includes:
Left unchecked, metabolic syndrome raises your risk for heart disease, stroke and other chronic conditions.
Not everyone experiences dramatic changes, but risk factors include:
Guidelines recommend regular monitoring to catch changes early. Your healthcare team usually checks:
Weight and Body Mass Index (BMI)
• Baseline measurement before starting Zyprexa
• Every month for the first three months
• Quarterly thereafter
Waist circumference
• Baseline and at least annually
Fasting blood glucose (or A1c)
• Baseline
• At 3 months
• Annually
Lipid panel (cholesterol and triglycerides)
• Baseline
• At 3 months
• Annually
Blood pressure
• With every office visit
Keeping track of these numbers helps you and your doctor spot trends and intervene early.
While some weight gain may be unavoidable, you can take steps to reduce its extent:
Nutrition
Physical Activity
Behavioral Tools
Medication Adjustments
Some changes warrant prompt discussion with your healthcare team:
If you ever experience severe symptoms—such as difficulty breathing, chest pain, significant mood swings or suicidal thoughts—seek medical help immediately. For non-urgent concerns, consider doing a free, online symptom check using the doctor-approved Ubie Symptom Checker to gather information before your visit.
Zyprexa can be a highly effective treatment for serious mental health conditions. For many people, the symptom relief outweighs the potential side effects. That said, staying proactive about lifestyle and monitoring can make a big difference in minimizing risks.
Medication decisions should be made in partnership with your healthcare provider. If you’re starting Zyprexa or already taking it, staying informed and proactive will help you get the most benefit while keeping side effects in check.
Speak to your doctor about any life-threatening or serious issues right away. If you have questions or want to check symptoms before your next appointment, consider a free, online symptom check using the doctor-approved Ubie Symptom Checker.
(References)
* Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58 Suppl 10:13-7. PMID: 9265911.
* Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine-induced weight gain. Ann Clin Psychiatry. 1998 Mar;10(1):39. doi: 10.1023/a:1026154730108. PMID: 9622049.
* Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol. 1999 Jun;19(3):273-5. doi: 10.1097/00004714-199906000-00014. PMID: 10350036.
* D'Amico G, Cedro C, Muscatello MR, Pandolfo G, Di Rosa AE, Zoccali R, La Torre D, D'Arrigo C, Spina E. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):619-23. doi: 10.1016/S0278-5846(03)00050-2. PMID: 12787848.
* Bloch Y, Vardi O, Mendlovic S, Levkovitz Y, Gothelf D, Ratzoni G. Hyperglycemia from olanzapine treatment in adolescents. J Child Adolesc Psychopharmacol. 2003 Spring;13(1):97-102. doi: 10.1089/104454603321666234. PMID: 12804130.
* Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19. PMID: 16172203.
* Dadić-Hero E, Ružić K, Grahovac T, Palijan TZ, Petranović D, Sepić-Grahovac D. Antipsychotic treatment--side-effect and/or metabolic syndrome. Psychiatr Danub. 2011 Mar;23(1):98-100. PMID: 21448108.
* Paik J. Olanzapine/Samidorphan: First Approval. Drugs. 2021 Aug;81(12):1431-1436. doi: 10.1007/s40265-021-01568-0. PMID: 34304374.
* Wu H, Siafis S, Hamza T, Schneider-Thoma J, Davis JM, Salanti G, Leucht S. Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. Schizophr Bull. 2022 May 7;48(3):643-654. doi: 10.1093/schbul/sbac001. PMID: 35137229; PMCID: PMC9077426.
* Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M, Govindarajalou R, Kt H, Ganesan P. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer. J Clin Oncol. 2023 May 10;41(14):2617-2627. doi: 10.1200/JCO.22.01997. Epub 2023 Mar 28. PMID: 36977285.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.